Phenolic Acid Phytochemicals as Potential Antiplatelet Agents: A Molecular Docking and ADME Study
DOI:
https://doi.org/10.65761/jbs.2026.60Keywords:
Phenolic acids; Antiplatelet agents; Molecular docking; ADME; PhytochemicalsAbstract
Background: Platelet hyperactivation and aggregation are major contributors to thrombotic cardiovascular and cerebrovascular diseases. Although conventional antiplatelet drugs are clinically effective, adverse effects and variable therapeutic responses have encouraged the search for safer natural alternatives. Phenolic acids are plant-derived phytochemicals with reported antioxidant, anti-inflammatory, and cardioprotective properties.
Objective: This study aimed to evaluate selected phenolic acid phytochemicals as potential antiplatelet agents using molecular docking and ADME prediction approaches.
Methods: Selected phenolic acids were subjected to molecular docking against platelet-associated protein targets to investigate their binding affinity, binding orientation, and interactions with important amino acid residues. ADME profiling was subsequently performed to assess their physicochemical, pharmacokinetic, and drug-likeness characteristics.
Results: The investigated phenolic acids demonstrated variable but generally favorable interactions with the selected targets. Several compounds showed strong predicted binding affinities and established hydrogen-bonding and hydrophobic interactions with functionally relevant residues. ADME analysis indicated that selected compounds possessed acceptable drug-like characteristics and pharmacokinetic profiles, although differences in gastrointestinal absorption and other properties were observed.
Conclusion: Phenolic acids demonstrate promising computational potential as antiplatelet candidates. Their favorable target interactions and acceptable ADME characteristics support further biochemical, cellular, and in vivo investigations to validate their antiplatelet efficacy and therapeutic safety.
References
1. Scridon A. Platelets and their role in hemostasis and thrombosis—from physiology to pathophysiology and therapeutic implications. Int J Mol Sci. 2022;23(21):12772. doi:10.3390/ijms232112772.
2. Chaudhary PK, Kim S, Kim S. An insight into recent advances on platelet function in health and disease. Int J Mol Sci. 2022;23(11):6022. doi:10.3390/ijms23116022.
3. Janus-Bell E, Mangin PH. The relative importance of platelet integrins in hemostasis, thrombosis and beyond. Haematologica. 2023;108(7):1734. doi:10.3324/haematol.2022.282136.
4. Sacchetti S, Puricelli C, Mennuni M, Zanotti V, Giacomini L, Giordano M, Dianzani U, Patti G, Rolla R. Research into new molecular mechanisms in thrombotic diseases paves the way for innovative therapeutic approaches. Int J Mol Sci. 2024;25(5):2523. doi:10.3390/ijms25052523.
5. Yamashita A, Asada Y. Underlying mechanisms of thrombus formation/growth in atherothrombosis and deep vein thrombosis. Pathol Int. 2023;73(2):65-80. doi:10.1111/pin.13305.
6. Gelbenegger G, Jilma B. Clinical pharmacology of antiplatelet drugs. Expert Rev Clin Pharmacol. 2022;15(10):1177-97. doi:10.1080/17512433.2022.2121702.
7. Oliva A, Cao D, Spirito A, Nicolas J, Pileggi B, Kamaleldin K, et al. Personalized approaches to antiplatelet treatment for cardiovascular diseases: an umbrella review. Pharmacogenomics Pers Med. 2023:973-90. doi:10.2147/PGPM.S391400.
8. Shpigelman J, Proshkina A, Daly MJ, Cox D. Personalized dual antiplatelet therapy in acute coronary syndromes: striking a balance between bleeding and thrombosis. Curr Cardiol Rep. 2023;25(7):693-710. doi:10.1007/s11886-023-01892-9.
9. Nappi F. P2Y12 receptor inhibitor for antiaggregant therapies: from molecular pathway to clinical application. Int J Mol Sci. 2024;25(14):7575. doi:10.3390/ijms25147575.
10. Chaachouay N, Zidane L. Plant-derived natural products: a source for drug discovery and development. Drugs Drug Candidates. 2024;3(1). doi:10.3390/ddc3010011.
11. Elshafie HS, Camele I, Mohamed AA. A comprehensive review on the biological, agricultural and pharmaceutical properties of secondary metabolites based-plant origin. Int J Mol Sci. 2023;24(4):3266. doi:10.3390/ijms24043266.
12. Santos-Buelga C, González-Paramás AM, González-Manzano S. Phenolic acids and derivatives: description, sources, properties, and applications. In: Natural Secondary Metabolites: From Nature, Through Science, to Industry. Cham: Springer International Publishing; 2023. p. 37-72. doi:10.1007/978-3-031-18587-8_3.
13. Saleem A, Akhtar MF, Sharif A, Akhtar B, Siddique R, Ashraf GM, et al. Anticancer, cardio-protective and anti-inflammatory potential of natural-sources-derived phenolic acids. Molecules. 2022;27(21):7286. doi:10.3390/molecules27217286.
14. Sehrawat R, Rathee P, Akkol EK, Khatkar S, Lather A, Redhu N, et al. Phenolic acids-versatile natural moiety with numerous biological applications. Curr Top Med Chem. 2022;22(18):1472-84. doi:10.2174/1568026622666220623114450.
15. Skroza D, Šimat V, Vrdoljak L, Jolić N, Skelin A, Čagalj M, et al. Investigation of antioxidant synergisms and antagonisms among phenolic acids in the model matrices using FRAP and ORAC methods. Antioxidants. 2022;11(9):1784. doi:10.3390/antiox11091784.
16. El-Saadony MT, Saad AM, Mohammed DM, Alkafaas SS, Abd El-Mageed TA, Fahmy MA, et al. Plant bioactive compounds: extraction, biological activities, immunological, nutritional aspects, food application, and human health benefits—a comprehensive review. Front Nutr. 2025;12:1659743. doi:10.3389/fnut.2025.1659743.
17. Negi R, Sharma B, Jan T, Kaur T, Khan SS, Yadav N, et al. Bioactive compounds as plant-based functional foods for human health: current scenario and future challenges. J Appl Biol Biotechnol. 2025;13(1):1-23. doi:10.7324/JABB.2024.180889.
18. Hou Y, Li H, Zhu L, Li Y, Zeng Y, Quan T, et al. A review of natural compounds to regulate platelet aggregation: molecular mechanism and research advance. Front Pharmacol. 2025;16:1537776. doi:10.3389/fphar.2025.1537776.
19. Sharifi-Rad J, Quispe C, Zam W, Kumar M, Cardoso SM, Pereira OR, et al. Phenolic bioactives as antiplatelet aggregation factors: the pivotal ingredients in maintaining cardiovascular health. Oxid Med Cell Longev. 2021;2021:2195902. doi:10.1155/2021/2195902.
20. Tian Y, Zong Y, Pang Y, Zheng Z, Ma Y, Zhang C, et al. Platelets and diseases: signal transduction and advances in targeted therapy. Signal Transduct Target Ther. 2025;10(1):159. doi:10.1038/s41392-025-02198-8.
21. Pollitt AY, Hughes CE, Jones CI. Platelet membrane receptors and signalling pathways. In: Antithrombotic and Antiplatelet Agents. 2025. p. 137-75. doi:10.1007/164_2025_787.
22. Li Z, Bi R, Sun S, Chen S, Chen J, Hu B, et al. The role of oxidative stress in acute ischemic stroke-related thrombosis. Oxid Med Cell Longev. 2022;2022:8418820. doi:10.1155/2022/8418820.
23. Olas B. The antioxidant, anti-platelet and anti-coagulant properties of phenolic compounds, associated with modulation of hemostasis and cardiovascular disease, and their possible effect on COVID-19. Nutrients. 2022;14(7):1390. doi:10.3390/nu14071390.
24. Lamponi S. Bioactive natural compounds with antiplatelet and anticoagulant activity and their potential role in the treatment of thrombotic disorders. Life. 2021;11(10):1095. doi:10.3390/life11101095.
25. Sharifi-Rad J, Quispe C, Shaheen S, El Haouari M, Azzini E, Butnariu M, et al. Flavonoids as potential anti-platelet aggregation agents: from biochemistry to health promoting abilities. Crit Rev Food Sci Nutr. 2022;62(29):8045-58. doi:10.1080/10408398.2021.1924612.
26. Fernandes DA, Gomes AN, Da Silva CM, de Medeiros Henriques IS, de Menezes RP, Scotti MT, et al. Natural phenolic compounds with antithrombotic and antiplatelet effects: a drug-likeness approach. Curr Med Chem. 2024;31(26):4138-59. doi:10.2174/0109298673268452231108061008.
27. Babalola OO, Bridget K, Oyubu G, Waheed SA, Ajiboye SA, Fakayode AE, et al. Integrating phytochemicals and in silico methods for modern drug discovery: a comprehensive review. Discov Chem. 2025;2(1):297. doi:10.1007/s44371-025-00373-y.
28. Agu PC, Afiukwa CA, Orji OU, Ezeh EM, Ofoke IH, Ogbu CO, et al. Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. Sci Rep. 2023;13(1):13398. doi:10.1038/s41598-023-40160-2.
29. Tran-Nguyen VK, Camproux AC. Computational modeling of protein-ligand interactions: from binding site identification to pose prediction and beyond. Curr Opin Struct Biol. 2025;95:103152. doi:10.1016/j.sbi.2025.103152.
30. Shahidi F, Dissanayaka CS. Phenolic-protein interactions: insight from in-silico analyses—a review. Food Prod Process Nutr. 2023;5(1):2. doi:10.1186/s43014-022-00121-0.
31. Pantaleão SQ, Fernandes PO, Gonçalves JE, Maltarollo VG, Honorio KM. Recent advances in the prediction of pharmacokinetics properties in drug design studies: a review. ChemMedChem. 2022;17(1):e202100542. doi:10.1002/cmdc.202100542.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Maaz Ahmad Shah, Asfandyar, Shahab Ur Rehman
This work is licensed under a Creative Commons Attribution 4.0 International License.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
